Literature DB >> 11112042

Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection.

A Buda1, A Caforio, F Calabrese, S Fagiuoli, S Pevere, U Livi, R Naccarato, P Burra.   

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are a well known complication after orthotopic heart transplantation (OHT). Although Epstein-Barr virus (EBV) infection has long been implicated in the pathogenesis of such disorders, other factors may play a part. Because of its lymphotropic properties, hepatitis C virus (HCV) may induce clonal expansion of B-lymphocytes and lead to PTLD. The aim of this study was to evaluate the potential association between HCV and EBV infection and PTLD in OHT patients. The retrospective study considered 404 adult patients screened for HCV. EBV serology, histology, and molecular analysis on tissue biopsies were performed in the PTLD patients (10/404, 2.5%). HCV positivity was found in 36/404 (8.9%) patients. The EBV genome was expressed on all neoplastic tissue samples analyzed. A higher proportion of HCV-positive patients developed PTLD than the HCV-negative cases (8% vs 2%, P = 0.017). EBV has a demonstrated role in the onset of PTLD, but HCV infection probably has to be considered as well.

Entities:  

Mesh:

Year:  2000        PMID: 11112042     DOI: 10.1007/s001470050371

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  11 in total

Review 1.  Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.

Authors:  Deepa Jagadeesh; Bruce A Woda; Jacqueline Draper; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 2.  Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.

Authors:  Albert Faye; Etienne Vilmer
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Plasmablastic lymphoma following transplantation.

Authors:  Michael J Van Vrancken; Latoya Keglovits; John Krause
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-04

4.  Hepatitis C virus related lymphoproliferative disorder in a renal transplant recipient.

Authors:  A N Aravindan; Venkatesh Moger; Vinay Sakhuja; Harbir S Kohli; Neelam Varma; Vivekanand Jha
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

5.  Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients.

Authors:  Lindsay M Morton; Ola Landgren; Nilanjan Chatterjee; David Castenson; Ruth Parsons; Robert N Hoover; Eric A Engels
Journal:  Blood       Date:  2007-09-12       Impact factor: 22.113

Review 6.  Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.

Authors:  Zeina Al-Mansour; Beverly P Nelson; Andrew M Evens
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

Review 7.  The post-transplant lymphoproliferative disorder-a literature review.

Authors:  Rokshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714

8.  Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation.

Authors:  Lisa Rausch; Christian Koenecke; Hans-Friedrich Koch; Alexander Kaltenborn; Nikos Emmanouilidis; Lars Pape; Frank Lehner; Viktor Arelin; Ulrich Baumann; Harald Schrem
Journal:  Transplant Res       Date:  2016-08-02

9.  Colorectal Cancer Characteristics and Outcomes after Solid Organ Transplantation.

Authors:  Amit Merchea; Faisal Shahjehan; Kristopher P Croome; Jordan J Cochuyt; Zhuo Li; Dorin T Colibaseanu; Pashtoon Murtaza Kasi
Journal:  J Oncol       Date:  2019-02-28       Impact factor: 4.375

10.  Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report.

Authors:  Fan Yu; Yuehua Huang; Yanying Wang; Zhuo Yu; Xinquan Li; Jiahong Dong
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.